Cargando…
Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota
Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is not well tolerated by psychosis patients. The prebiotic, B-GOS(®), attenuates metabolic dysfunction in obese subjects, and in rodents, alters central NMDA receptors and may affect serotonin receptors tha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852210/ https://www.ncbi.nlm.nih.gov/pubmed/29540664 http://dx.doi.org/10.1038/s41398-018-0116-8 |
_version_ | 1783306524515368960 |
---|---|
author | Kao, Amy Chia-Ching Spitzer, Sonia Anthony, Daniel C. Lennox, Belinda Burnet, Philip W. J. |
author_facet | Kao, Amy Chia-Ching Spitzer, Sonia Anthony, Daniel C. Lennox, Belinda Burnet, Philip W. J. |
author_sort | Kao, Amy Chia-Ching |
collection | PubMed |
description | Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is not well tolerated by psychosis patients. The prebiotic, B-GOS(®), attenuates metabolic dysfunction in obese subjects, and in rodents, alters central NMDA receptors and may affect serotonin receptors that are relevant in psychosis. We have determined whether B-GOS(®) influenced olanzapine-associated weight gain and central NMDA and serotonin receptors. Circulating acetate, IL-1β, IL-8 and TNFα, liver acetyl-CoA carboxylase (ACC), white adipose tissue (WAT) acetate receptor GPR43, and specific faecal bacteria genera were also measured to provide mechanistic information. Adult female Sprague-Dawley rats were administered a B-GOS(®) (0.5 g/kg/day) solution or water for 21 days, and received a single, daily, intraperitoneal injection of olanzapine or saline on days 8–21. The intake of B-GOS(®) significantly attenuated olanzapine-induced weight gain without altering frontal cortex 5-HT2AR blockade. Cortical GluN1 levels were elevated by olanzapine in the presence of B-GOS(®). Plasma acetate concentrations increased following B-GOS(®) or olanzapine administration alone, but reduced when prebiotic and drug were administered in combination. This pattern was paralleled by hepatic ACC mRNA expression. The abundance of WAT GPR43 mRNA was reduced by olanzapine, only in the absence of B-GOS(®). Co-administration of B-GOS(®) and olanzapine also elevated plasma TNFα, which is reported to influence lipid metabolism. Finally, B-GOS(®) elevated faecal Bifidobacterium spp. and reduced some bacteria in the Firmicutes phylum, whilst olanzapine treatment either alone or with B-GOS(®), was without effect. These data suggest that inclusion of B-GOS(®) as an adjunct to olanzapine treatment in schizophrenia may prevent weight gain and have benefits on cognitive function in psychosis. The role of acetate in these effects requires further investigation. |
format | Online Article Text |
id | pubmed-5852210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58522102018-03-15 Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota Kao, Amy Chia-Ching Spitzer, Sonia Anthony, Daniel C. Lennox, Belinda Burnet, Philip W. J. Transl Psychiatry Article Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is not well tolerated by psychosis patients. The prebiotic, B-GOS(®), attenuates metabolic dysfunction in obese subjects, and in rodents, alters central NMDA receptors and may affect serotonin receptors that are relevant in psychosis. We have determined whether B-GOS(®) influenced olanzapine-associated weight gain and central NMDA and serotonin receptors. Circulating acetate, IL-1β, IL-8 and TNFα, liver acetyl-CoA carboxylase (ACC), white adipose tissue (WAT) acetate receptor GPR43, and specific faecal bacteria genera were also measured to provide mechanistic information. Adult female Sprague-Dawley rats were administered a B-GOS(®) (0.5 g/kg/day) solution or water for 21 days, and received a single, daily, intraperitoneal injection of olanzapine or saline on days 8–21. The intake of B-GOS(®) significantly attenuated olanzapine-induced weight gain without altering frontal cortex 5-HT2AR blockade. Cortical GluN1 levels were elevated by olanzapine in the presence of B-GOS(®). Plasma acetate concentrations increased following B-GOS(®) or olanzapine administration alone, but reduced when prebiotic and drug were administered in combination. This pattern was paralleled by hepatic ACC mRNA expression. The abundance of WAT GPR43 mRNA was reduced by olanzapine, only in the absence of B-GOS(®). Co-administration of B-GOS(®) and olanzapine also elevated plasma TNFα, which is reported to influence lipid metabolism. Finally, B-GOS(®) elevated faecal Bifidobacterium spp. and reduced some bacteria in the Firmicutes phylum, whilst olanzapine treatment either alone or with B-GOS(®), was without effect. These data suggest that inclusion of B-GOS(®) as an adjunct to olanzapine treatment in schizophrenia may prevent weight gain and have benefits on cognitive function in psychosis. The role of acetate in these effects requires further investigation. Nature Publishing Group UK 2018-03-15 /pmc/articles/PMC5852210/ /pubmed/29540664 http://dx.doi.org/10.1038/s41398-018-0116-8 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kao, Amy Chia-Ching Spitzer, Sonia Anthony, Daniel C. Lennox, Belinda Burnet, Philip W. J. Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title_full | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title_fullStr | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title_full_unstemmed | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title_short | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
title_sort | prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852210/ https://www.ncbi.nlm.nih.gov/pubmed/29540664 http://dx.doi.org/10.1038/s41398-018-0116-8 |
work_keys_str_mv | AT kaoamychiaching prebioticattenuationofolanzapineinducedweightgaininratsanalysisofcentralandperipheralbiomarkersandgutmicrobiota AT spitzersonia prebioticattenuationofolanzapineinducedweightgaininratsanalysisofcentralandperipheralbiomarkersandgutmicrobiota AT anthonydanielc prebioticattenuationofolanzapineinducedweightgaininratsanalysisofcentralandperipheralbiomarkersandgutmicrobiota AT lennoxbelinda prebioticattenuationofolanzapineinducedweightgaininratsanalysisofcentralandperipheralbiomarkersandgutmicrobiota AT burnetphilipwj prebioticattenuationofolanzapineinducedweightgaininratsanalysisofcentralandperipheralbiomarkersandgutmicrobiota |